Status:
COMPLETED
OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA
Lead Sponsor:
Bernadette Dian Novita, MD.,PhD
Conditions:
Duration of Hospitalization
Clinical Manifestation of COVID-19
Eligibility:
All Genders
18-97 years
Brief Summary
In order to compare the effectiveness between Remdesivir and Favipiravir, an observational analytic study using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients from Ja...
Detailed Description
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2). Antiviral therapies are considered to be one of the COVID-19 treatm...
Eligibility Criteria
Inclusion
- Adult patients (eighteen years old or above) with moderate to severe COVID-19 (categorized based on KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR HK. 01. 07/MENKES/413/2020);
- Admitted to Gotong Royong Hospital Surabaya from January 2021 to August 2021;
- Received remdesivir OR favipiravir with minimal five days of treatment
- Not in pregnancy and lactating condition
Exclusion
- female patient with pregnancy and lactation
- patient whom was passed away or forced home during two-weeks observation period
Key Trial Info
Start Date :
August 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 25 2021
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT05222113
Start Date
August 1 2021
End Date
September 25 2021
Last Update
February 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gotong Royong Surabaya Hospital
Surabaya, East Java, Indonesia, 60119